Biosimilars significantly reduce health care costs in Australia, enhancing access to biologics while driving price ...

A study reveals that switching from Humira to Amgevita for IBD maintains disease control and offers significant cost savings.

A new biosimilar, SYSA1902, shows comparable efficacy and safety to ustekinumab for treating moderate-to-severe plaque psoriasis, expanding patient options.

A recent Japanese study confirms that switching from originator infliximab to biosimilars maintains remission in patients who ...

A new biosimilar for aflibercept shows similar efficacy and safety in treating neovascular age-related macular degeneration ...

August 2025 brought significant advancements in biosimilars, including financial successes, new product launches, and research on ongoing challenges in market access.

New denosumab biosimilars, Bildyos and Bilprevda, enhance access to affordable osteoporosis and bone disease treatments, promising significant patient benefits.

Number 1: The competitive landscape for bone health treatments in the US has intensified with the FDA approval of Bildyos ...

Alvotech achieves a remarkable financial turnaround in 2025, reporting a net profit driven by strong biosimilar sales and strategic partnerships. Alvotech, an Iceland-based biosimilar-focused biotech ...

Canadian study reveals no significant differences in remission outcomes between etanercept biosimilars and the originator, Enbrel, for rheumatoid arthritis patients. As the US continues to wait for ...